Inactive Instrument

News PharmaCyte Biotech, Inc. Other OTC

Equities

PMCB

US71715X1046

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

PharmaCyte Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	Mar. 18	CI
PharmaCyte Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	Dec. 15	CI
Femasys Inc. announced that it has received $6.85 million in funding from PharmaCyte Biotech, Inc. and other investors	Nov. 21	CI
Femasys Inc. announces tranche update	Nov. 16	CI
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.	Nov. 16	AQ
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.	Nov. 15	BU
Femasys Inc. announced that it expects to receive $6.85 million in funding from PharmaCyte Biotech, Inc.	Nov. 13	CI
PharmaCyte Biotech : Change in Certifying Accountants - Form 8-K	Nov. 09	PU
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology	23-10-31	BU
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology	23-10-31	BU
PharmaCyte Biotech, Inc. Provides Corporate Update on Cell-In-A-Box Technology	23-10-31	CI
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023.	23-09-18	CI
PharmaCyte Biotech, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023	23-09-18	CI
PharmaCyte Biotech : Certificate of Incorporation/Bylaws - Form 8-K	23-09-07	PU
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023.	23-07-31	CI
PharmaCyte Biotech, Inc. Reports Earnings Results for the Full Year Ended April 30, 2023	23-07-31	CI
Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on May 11, 2023.	23-06-15	CI
PharmaCyte Biotech Announces Final Results of Tender Offer	23-06-15	BU
PharmaCyte Biotech, Inc.'s Equity Buyback announced on May 11, 2023, has closed with 8,085,879 shares, representing 48.15% for $26.46 million.	23-06-08	CI
PHARMACYTE BIOTECH, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)	23-05-11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News PharmaCyte Biotech, Inc. Other OTC

Equities

PMCB

US71715X1046

Summary

Filters